EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX: NBY) a clinical stage biopharmaceutical company, gave more details today on its dermatology program. Dr. Ron Najafi, Chairman and CEO, said that “NovaBay is now accelerating its efforts in dermatology. We formed our DermaBay subsidiary in 2007, to build up our expertise and move forward in dermatology. Our Aganocide® compounds have appeared all along to be of significant potential interest in dermatology, but we needed to deliver the compounds in acceptable dermatological formulations. We now have the necessary capabilities to proceed with product development in dermatology.”
